Haemadin
Picomolar-affinity thrombin inhibitor from Indian buffalo leech — distinct mechanism from hirudin.
Preclínico / mecanísticoLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Picomolar-affinity thrombin inhibitor from Indian buffalo leech — distinct mechanism from hirudin.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Haemadin's in vitro thrombin inhibition does not establish clinical efficacy. No FDA-approved derivative exists. Mechanism is preclinical/biochemical only.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 5,183 Da
- Source species
- Haemadipsa sylvestris
- Discovered
- 1991 · Strube KH et al.
- PDB structures
- 1E0F
Biological Targets
- → thrombin (exosite I, non-exosite II)
Key Citations
- Strube KH et al. (1993), J Biol Chem · PMID 8473305
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.